Company
Penumbra
NYSE: PEN
Alameda, California device maker founded in 2004 on stroke thrombectomy (NYSE: PEN); its aspiration platform now covers arterial, pulmonary and venous clot removal, including this DVT indication.
2 stories
Regulatory News has published 2 stories about Penumbra on 25 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 25 October 2026.
This page is generated from Regulatory News’ editorial coverage of Penumbra. It is not an advertisement.
On the record
- Company
- Penumbra, Inc. (NYSE: PEN)
- Headquarters
- Alameda, California
- Founded
- 2004, by Arani Bose, MD, and Adam Elsesser
- Regulator
- U.S. Food and Drug Administration (CDRH)
- Latest milestone
- FDA clearance, Lightning CAVT for deep vein thrombosis
Each line is taken from the most recent story of ours that states it.
